UNSPSC 51385805: Piroxicam

This classification denotes a cyclooxygenase inhibitor and aromatic compound with the molecular formula C15H13N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 13T4O6VMAM, chemically known as 4-hydroxy-2-methyl-n-2-pyridyl-2h-1,2-benzothiazine-3-carboxamide 1,1-dioxide but generally known as piroxicam, which bears US NIH Compound Identifier 5280452. European Medicines Agency schedules Piroxicam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09936MIG.

UNSPSC 51385805 Piroxicam is a Commodity code, though recent state and local procurement activity under this code shows little direct solicitation for the specific active pharmaceutical ingredient piroxicam itself. Instead, state and local governments are acquiring pharmaceuticals and related health products through broader multi-source generic drug procurement frameworks, naloxone-focused community health initiatives, and pharmacy benefit program modernization efforts. The issuing bodies span state health agencies, county health departments, and regional cooperative purchasing alliances—organizations responsible for managing pharmaceutical supply chains and community health interventions across multiple jurisdictions. The kinds of work actually being solicited under this code's broader pharmaceutical category include generic drug supply contracts with wholesaler networks, opioid-reversal agent procurement for emergency response and community health, and exploratory pharmacy benefit direct-to-manufacturer contracting programs designed to reduce intermediary costs and improve prescription fulfillment efficiency.

Minnesota's MMCAP cooperative purchasing initiative (posted January 20, 2026, with a March 26, 2026 response deadline) is establishing multi-award contracts for generic pharmaceuticals and OTC products across state and local government facilities in Minnesota and Oregon, requiring vendors to supply through three authorized wholesalers with fixed and competitive pricing evaluated at 75 percent weight. Seminole County, Florida released an IFB on June 30, 2026 (response due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the county community health building and terms including a two-year initial contract with one-year renewal option. Texas Health and Human Services Commission issued an RFI in April 2026 to gather vendor capability information on direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager arrangements, signaling early-stage state procurement strategy development in this category. Geographic activity centers on Minnesota, Texas, and Florida; the cooperative purchasing model suggests ongoing expansion across additional states participating in multistate alliances.